

IPW/1625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Iwao Ojima Examiner: Unassigned
Serial No.: 10/577,573 Group Art Unit: Unassigned
Confirmation No: 6749 Docket: 178-330 PCT/US
Filed: April 27, 2006 Dated: March 23, 2007
For: Taxoid-Fatty Acid Conjugates
and Pharmaceutical
Compositions Thereof

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to: Commissioner
for Patents, P.O. Box 1450, Alexandria, Virginia
22313-1450 on March 23, 2007

Signed: Dearna J. Geller

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.
§1.56, Applicant submits herewith the following Information Disclosure Statement in
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

The references are listed on Applicant's Form PTO-1449, which is attached to this
Information Disclosure Statement for the convenience of the Examiner. Applicant requests
consideration of each of the documents listed on the attached Form PTO-1449, and that such
consideration be indicated by initialing each citation thereon.

Copies of each of the non-patent publications are enclosed herewith for the
convenience of the Examiner.

Applicant: Iwao Ojima
Serial No.: 10/577,573
Filed: April 27, 2006
Page 2 of 2

The Shashoua, et al. reference (U.S. Patent No. 5,795,909) was listed in the International Search Report issued in the corresponding International Application. A copy of the International Search Report accompanies this IDS.

This Statement is being filed before the mailing of a first Office Action on the merits. Applicant believes that no fee for this submission is due. If, however, a fee is due for entry of this Information Disclosure Statement, the Office is authorized to charge Deposit Account No. 08-2461 for any such fee.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicant's attorney at the telephone number set forth below.

Respectfully submitted,



Linda D. Chin
Registration No.: 58,205
Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
LDC/dlg
234900_1



FORM PTO-146A U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO. 178-330 PCT/US	SERIAL NO. 10/577,573
		APPLICANT Iwao Ojima	CONFIRMATION NO. 6749
		FILING DATE April 27, 2006	GROUP Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	5,919,815	July 6, 1999	Bradley, et al.			
	6,080,877	June 27, 2000	Swindell et al.			
	5,795,909	August 18, 1998	Shashoua et al.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		1	Bradley, et al. "Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel" <i>Clinical Cancer Research</i> Vol. 7:3229-3238 (2001)
		2	Interview with Nigel Webb "Better Benefits, Fewer Risks", Pharmaceutical Executive May 2001.
		3	Ojima, et al. "Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids," <i>Bioorg. Med. Chem. Lett.</i> , 9:3423-3428 (1999)
		4	Ojima, et al. "Synthesis and Struture-Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells," <i>J. Med. Chem.</i> 39:3889-3896 (1996).
		5	Vredenburg, et al. "Effects of Orally Active Taxanes on P-Glycoprotein Modulation and Colon and Breast Carcinoma Drug Resistance," <i>Journal of the National Cancer Institute</i> 93(16):1234-1245 (August 2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.